Lifeline Biotechnologies, Inc. of Reno said last week it agreed to sell its early-detection cancer product line to Solos Endoscopy for $4 million in restricted shares in publicly traded Solos.
Lifeline, also publicly held, said it will receive royalty payments from Boston-based Solos once product sales exceed $4 million.
Comments
Use the comment form below to begin a discussion about this content.
Sign in to comment